Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus PRED MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVELTYS versus PRED MILD.
INVELTYS vs PRED MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid